The National Institutes of Health (NIH) is espousing the benefits of an AEG 12 mosquito protein study authorities said could help develop treatments to combat life-threatening viruses.
Researchers at the NIH's National Institute of Environmental Health Sciences (NIEHS) used X-ray crystallography... Read More »
A study focused on determining whether patients would benefit from a booster for the Moderna, Inc. COVID-19 vaccine has enrolled and dosed its first participants this week.
Moderna’s mRNA COVID-19 vaccine is currently in use across the U.S. and has shown high efficacy against the original... Read More »
Building on its efforts during the ongoing COVID-19 pandemic, the Coalition for Epidemic Preparedness Innovations (CEPI) has proposed a $3.5 billion plan to reduce or eliminate future pandemic and epidemic risk through preparedness investment over the next five years.
The organization has sought... Read More »
A professor from Johns Hopkins Center for Health and Security testified before the Maryland General Assembly on the certification of gene synthesis providers and manufacturers of gene synthesis equipment.
Dr. Gigi Gronvall -- senior scholar at the Johns Hopkins Center for Health Security and... Read More »
Research and development company Battelle announced Tuesday that it had developed a microneutralization assay that uses live SARS-CoV-2 virus to analyze the neutralizing response against the virus in human serum samples.
The assay allows the company to test samples from vaccine clinical trials.... Read More »
CARB-X could award up to $3.5 million, plus up to $18.5 million for successful development milestones, to Affinivax for a vaccine for Staphylococcus aureus bacterial infections, for which treatment options are currently limited.
No vaccine presently exists for S. aureus, despite the high threat... Read More »
U.S. Sen. Jacky Rosen (D-NV) recently co-sponsored legislation to fund the Prevention and Public Health Fund (PPHF), which includes programs aimed and preventing and responding to pandemics.
The Public Health Funding Prevents Pandemics Act would ensure the PPHF, part of the Affordable Care Act,... Read More »
Valneva and Pfizer are getting set to launch a new Phase 2 study on VLA-15, their vaccine candidate for Lyme disease.
The study, VLA15-221, builds on previous positive Phase 2 studies. It incorporates new dose regimens and is anticipated to be the final Phase 2 study before deciding to progress... Read More »
According to a new report from the U.S. Centers for Disease Control and Prevention (CDC) and the University of Utah, the costs of antibiotic resistance among diseases are growing, leading to billions of dollars in health care costs and increasing rates of infections.
According to “National... Read More »
A new deal reached between Baxter BioPharma Solutions and Moderna, Inc. this week will see Baxter handle fill/finish services for Moderna’s COVID-19 vaccine in the United States, ultimately providing between 60-90 million doses this year.
Baxter’s Indiana facility will handle the... Read More »
A molecular test for COVID-19 can now be used at home without a prescription, following the U.S. Food and Drug Administration’s (FDA) granting of emergency use authorization (EUA) to the Cue COVID-19 Test for Home and Over the Counter (OTC) Use.
A molecular nucleic acid amplification test... Read More »
The preliminary results of a Phase 2a randomized, double-blind trial of the Merck and Ridgeback Biotherapeutics-created oral antiviral for the treatment of COVID-19, molnupiravir, have shown the ability to quickly decrease the infectious virus among patients.
While full results are pending, this... Read More »
Through a deal between the World Health Organization and others with GSK, a rotavirus vaccine will be available to more children living in low-income nations facing humanitarian crises.
The agreement makes use of the multi-partner Humanitarian Mechanism, launched in 2017, where manufacturers... Read More »
New research from the Washington University School of Medicine in St. Louis seemingly confirms scientists' and health experts' worst fear that all three of the prominent, fast-spreading variants of COVID-19 can resist vaccines and antibodies currently effective against their forebear.
Published... Read More »
Under a new agreement, Novartis will manufacture the mRNA and bulk drug product for CureVac’s CVnCoV vaccine candidate for COVID-19, with a goal of up to 50 million doses by the end of 2021.
“I am very pleased that with Novartis, we have found another highly experienced partner to support... Read More »
Research from Battelle shows that wastewater analysis can pinpoint neighborhoods that are hotspots for viral outbreaks of COVID-19.
A preliminary report was preprinted on Feb. 20 in the MedRxIv found that by testing wastewater for the presence of SARS-COV-2 and other pathogens, they were able... Read More »
In a new study published on bioRxiv, Soligenix, Inc. reported that its CiVax COVID-19 vaccine demonstrated rapid, broad-spectrum, neutralizing antibody and immunity onset in preclinical studies.
The head stable vaccine used full-length Spike protein antigens to do its work, and at least in... Read More »
The Biomedical Advanced Research and Development Authority (BARDA) and Hologic, Inc. are working together to develop the Panther Fusion SARS-CoV-2/Flu/RSV assay, intended to be able to simultaneously detect and differentiate a variety of viruses from a single sample.
While SARS-CoV-2 is a major... Read More »
The biopharmaceutical company AstraZeneca said it has initiated steps to provide broad and equitable access to the COVID-19 vaccine, noting doses have begun arriving globally in low and middle-income countries.
“These first steps towards fulfilling our broad, equitable, and no-profit emergency... Read More »
A team, including GE Research, the Broad Institute, DNA Script, MEDInstill, Molecular Assemblies, and the University of Washington, has been awarded a five-year, up to $41 million contract from the Defense Advanced Research Projects Agency (DARPA) to create a new, quicker vaccine production... Read More »
The COVID-19 pandemic has hit a critical stage, according to the Infectious Diseases Society of America (IDSA), and as such, the $1.9 billion American Rescue Plan touted by the Biden Administration and advanced by the House last week represents a welcome boost.
“This legislation represents... Read More »
In what Johnson & Johnson CEO Alex Gorsky called a great example for the larger pharmaceutical industry, the company has reached a deal with fellow pharmaceutical giant and oft-rival Merck that will unite the pair’s resources to produce Johnson & Johnson’s new COVID-19 vaccine.
Faced... Read More »
The Biden administration helped forge a deal between Merck and Johnson & Johnson (J&J) to expand production of J&J’s COVID-19 vaccine, which is expected to help the company deliver 100 million doses by the end of May instead of its previous June goal.
The collaboration between the... Read More »
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) awarded up to $18 million to GSK Biologicals and its affiliate GSK Vaccines Institute for Global Health (GVGH) to develop new vaccines for two different illnesses.
One is a vaccine for Group A streptococcus... Read More »
The National Institutes of Health (NIH) has earmarked funding totaling nearly $33 million over four years for five University of California San Diego Rapid Acceleration of Diagnostics (RADx) projects.
The RADx initiative seeks to expedite the development, commercialization, and implementation of... Read More »
The Biomedical Advanced Research and Development Authority (BARDA) recently partnered with LightDeck Diagnostics to create a six-minute SARS-CoV-2 antigen test usable without the need for a full diagnostic laboratory.
This point of care test could be used for on-site screening of suspected... Read More »
The U.S. Food and Drug Administration (FDA) granted emergency use authorization Monday for the Quidel QuickVue At-Home COVID-19 Test.
An antigen test, QuickVue will allow users suspected of having COVID-19 by their healthcare provider within the first six days of symptom onset to quickly collect... Read More »
U.S. Rep. Tom Reed (R-NY) introduced a $163 billion bill to funds efforts to mitigate the effects of COVID-19.
The Crush The Virus Act (H.R. 1371) provides $163 billion in funding to increase the distribution and administration of COVID-19 vaccines, boost access to COVID-19 testing throughout... Read More »
The U.S. Food and Drug Administration (FDA) announced this week that undiluted frozen vials of the Pfizer-BioNTech COVID-19 vaccine will now be allowed to be transported and stored at conventional pharmaceutical freezer temperatures for up to two weeks.
While the preferred storage for this... Read More »
The United States will now benefit from the rollout of a third COVID-19 vaccine, following last week’s emergency use authorization (EUA) of the Janssen vaccine by the U.S. Food and Drug Administration (FDA).
That decision came in the wake of recommendations from an advisory panel known as the... Read More »
A new report from Johns Hopkins Center for Health Security found that emergency departments in New York City hospitals were overwhelmed and struggled to maintain conventional standards of care during the COVID-19 pandemic.
The report, “Crisis Standards of Care: Lessons from New York City... Read More »
Regeneron Pharmaceuticals is making changes to the Phase 3 trial of its Regen-COV treatment for outpatients with COVID-19.
The changes come at the recommendation of the Independent Data Monitoring Committee (IDMC), which said to no longer use a placebo group in the trial. IDMC found clear... Read More »
Pfizer Inc. and BioNTech announced the beginning of an evaluation into the safety and immunogenicity of a third dose of their COVID-19 vaccine last week to study the effects of a booster vaccine against emerging SARS-CoV-2 variants.
This will be offered to up to 144 participants from the phase... Read More »
The Food and Drug Administration (FDA) is holding an advisory committee meeting on Friday during which the committee is expected to recommend a single-dose Johnson & Johnson (J&J)-Janssen Biotech SARS-CoV-2 vaccine to become the third COVID-19 vaccine available for emergency use to... Read More »
The first 600,000 doses of the AstraZeneca/Oxford COVID-19 vaccine allocated to the COVAX Facility have been delivered to Ghana, with further deliveries expected to reach Cote d’Ivoire later this week.
It marks the beginning of a global rollout long in the planning and the first COVAX vaccine... Read More »